Claris Law Legal Blogging Community

Recent Entries

RSS 2.0 feed Add to My Yahoo!
Add to Bloglines Add to your My Feedster
Add to your NewsGator My MSN
Asbestos Mesothelioma Lawyer

Mesomark-A New Test For The Early Detection Of Mesothelioma

editor photo

Editor: Brandon West
Profession: Brayton Purcell LLP

March 06, 2007

By Brandon Smith

TrackBack (0)

Category: Mesothelioma News

For those affected by the deadly cancer of mesothelioma after prolonged exposure to asbestos containing fibers and products, Mesomark might just be the newest aid in monitoring and controlling the fatal disease. Since its approval for humanitarian use in the United States by the U.S. Food and Drug Administration in January of this year, many all over the world have already benefited from it use. Manufactured by Fujirebio Diagnostics, (FDI) Mesomark is a new blood testing kit designed to detect Soluble Mesothelin-Related Peptides (SMRP) in human serum. When evaluated over time, it is said to be useful in determining who might develop mesothelioma and further monitor the condition in those that already do.

The following information is contained on the Mesomark website:

What is the MESOMARK assay and how does it relate to mesothelioma?The MESOMARK assay is a simple blood test, using an Enzyme-Linked Immunosorbent Assay (ELISA) format, for the quantitative measurement of Soluble Mesothelin-Related Peptides (SMRP) in human serum. SMRP is a biomarker produced by mesothelioma cells that can be elevated in the serum of patients suffering from mesothelioma.

Why is the MESOMARK test performed?The MESOMARK test is performed to measure the level of SMRP present in the serum. The MESOMARK blood test will be used to help determine the presence of mesothelioma. The MESOMARK test can also help measure a mesothelioma patient's response to therapy and determine if additional testing is required.

What do the results of the MESOMARK test mean?Physicians use the MESOMARK test results to assist them in making decisions about the management of patients with mesothelioma. Increasing results may be indicative of progressive disease conditions; decreasing or constant results may be indicative of response to therapy, or stable disease.

Trackback Pings

TrackBack URL for this entry:
http://myblog.clarislaw.com/usa/mt-tb.cgi/1297

Email Article



(optional):